Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | EVP, Chief Scientific Ofc, COO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,435 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 18,000 · Balance 163,435 Row 2 · 2026-10-05 · Sale · Disposed 18,000 · Balance 145,435 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2030-04-17 | Direct | 46,398 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 18,000 · Balance 46,398 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F2: Stock Option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 21, 2024
Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 3,695 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 7,392 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 44,556 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 5, 2023 21:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,067 | $51.46 | $54,907.82 |
DisclosureSEC source: 0001209191-23-057402 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,868 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.185 to $52.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-23-057402 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-054327 · doc4.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 122 | $48.12 | $5,870.52 |
DisclosureSEC source: 0001209191-23-054327 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $48.10 to $48.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,878 | $47.22 | $135,907.79 |
DisclosureSEC source: 0001209191-23-054327 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $47.00 to $47.705. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-23-054327 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2023 Filed Oct 16, 2023 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-052850 · doc4.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,555 Underlying: Common Stock · 5,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 12, 2023 Filed Oct 16, 2023 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $2.42 | $12,100.00 |
DisclosureSEC source: 0001209191-23-052850 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-051895 · doc4.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 850 | $51.56 | $43,826.00 |
DisclosureSEC source: 0001209191-23-051895 · doc4.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,935 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.39 to $51.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 608 | $50.74 | $30,849.92 |
DisclosureSEC source: 0001209191-23-051895 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,785 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.31 to $51.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,542 | $49.69 | $76,621.98 |
DisclosureSEC source: 0001209191-23-051895 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,393 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.19 to $50.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-23-051895 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 20:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-050573 · doc4.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 20:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-23-050573 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,131 | $51.00 | $108,681.00 |
DisclosureSEC source: 0001209191-23-048467 · doc4.xml · nonDerivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,935 F5 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-23-048467 · doc4.xml · derivative · entry 5 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,555 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 323 | $53.36 | $17,235.28 |
DisclosureSEC source: 0001209191-23-048467 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,066 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $53.28 to $53.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,677 | $52.75 | $141,211.75 |
DisclosureSEC source: 0001209191-23-048467 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,389 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.27 to $53.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-23-048467 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:45 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001209191-23-035461 · doc4.xml · derivative · entry 1 Wassil Jim · CIK 0001813798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 6, 2023, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,189 | $41.49 | $49,331.61 |
DisclosureSEC source: 0001209191-23-015720 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,026 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $41.67 | $0.00 |
DisclosureSEC source: 0001209191-23-015720 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015720 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,215 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000954 · doc4.xml · derivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-12-30 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 22:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 105,371 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-062845 · doc4.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,555 Underlying: Common Stock · 105,371 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 22:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 105,371 | $2.42 | $254,997.82 |
DisclosureSEC source: 0001209191-22-062845 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Common Stock received upon this option exercise remain subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 24, 2022. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-054088 · doc4.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,926 Underlying: Common Stock · 2,800 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,926 | $25.91 | $49,893.03 |
DisclosureSEC source: 0001209191-22-054088 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,344 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.685 to $26.205. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 874 | $25.31 | $22,123.56 |
DisclosureSEC source: 0001209191-22-054088 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,270 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.68 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,800 | $2.42 | $6,776.00 |
DisclosureSEC source: 0001209191-22-054088 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-050943 · doc4.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,726 Underlying: Common Stock · 2,800 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 120 | $26.56 | $3,187.20 |
DisclosureSEC source: 0001209191-22-050943 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,344 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,680 | $26.09 | $69,923.88 |
DisclosureSEC source: 0001209191-22-050943 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,464 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.56 to $26.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,800 | $2.42 | $6,776.00 |
DisclosureSEC source: 0001209191-22-050943 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:34 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,162 | $26.38 | $57,033.56 |
DisclosureSEC source: 0001209191-22-049022 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,344 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-046841 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,526 Underlying: Common Stock · 2,800 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,800 | $25.15 | $70,407.12 |
DisclosureSEC source: 0001209191-22-046841 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,506 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.02 to $25.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,800 | $2.42 | $6,776.00 |
DisclosureSEC source: 0001209191-22-046841 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-041149 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,326 Underlying: Common Stock · 2,800 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,800 | $22.00 | $61,600.00 |
DisclosureSEC source: 0001209191-22-041149 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,506 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,800 | $2.42 | $6,776.00 |
DisclosureSEC source: 0001209191-22-041149 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,562 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2022. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:10 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 44,556 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001209191-22-036758 · doc4.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,556 Underlying: Common Stock · 44,556 shares Expires 2032-06-09 F2 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following June 10, 2022, the vesting commencement date, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:10 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 11,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036758 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,087 F1 · shares: Represents restricted stock units ("RSUs") granted on June 10, 2022. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of June 10, 2022, the vesting commencement date, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Vesting of the RSUs shall accelerate upon a Change of Control (as defined in the Icosavax, Inc. 2021 Incentive Award Plan). Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-025016 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,126 Underlying: Common Stock · 2,800 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,800 | $23.98 | $67,130.00 |
DisclosureSEC source: 0001209191-22-025016 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,944 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.69 to $24.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,800 | $2.42 | $6,776.00 |
DisclosureSEC source: 0001209191-22-025016 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016527 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016527 · doc4.xml · derivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: 12/48 of shares subject to the option vest on February 15, 2023, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016527 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,944 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.